“The results from this study validate existing evidence of the efficacy of PoNS across clinical data and real-world utilization of the therapy by demonstrating durability of effect as further ...

PoNS therapy is currently available in the United States as a treatment for gait deficit due to MS for patients 22 years and older, and in Canada and Australia for additional indications. The ...

The FDA granted breakthrough therapy designation to an autologous CAR-T cell therapy for pediatric patients with diffuse ...

Breakthrough Therapy Designation is based on the encouraging ... is a primary high-grade brain tumor that arises in the pons and is uniformly fatal. DIPG affects approximately 300 children per ...